Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma.
Borchert S, Suckrau PM, Walter RFH, Wessolly M, Mairinger E, Steinborn J, Hegedus B, Hager T, Herold T, Eberhardt WEE, Wohlschlaeger J, Aigner C, Bankfalvi A, Schmid KW, Mairinger FD. Borchert S, et al. Among authors: hegedus b. Sci Rep. 2020 Oct 29;10(1):18677. doi: 10.1038/s41598-020-75807-x. Sci Rep. 2020. PMID: 33122816 Free PMC article.
Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis.
Ghanim B, Hoda MA, Winter MP, Klikovits T, Alimohammadi A, Hegedus B, Dome B, Grusch M, Arns M, Schenk P, Pohl W, Zielinski C, Filipits M, Klepetko W, Berger W. Ghanim B, et al. Among authors: hegedus b. Ann Surg. 2012 Aug;256(2):357-62. doi: 10.1097/SLA.0b013e3182602af4. Ann Surg. 2012. PMID: 22750759
Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells.
Hoda MA, Münzker J, Ghanim B, Schelch K, Klikovits T, Laszlo V, Sahin E, Bedeir A, Lackner A, Dome B, Setinek U, Filipits M, Eisenbauer M, Kenessey I, Török S, Garay T, Hegedus B, Catania A, Taghavi S, Klepetko W, Berger W, Grusch M. Hoda MA, et al. Among authors: hegedus b. Br J Cancer. 2012 Dec 4;107(12):1978-86. doi: 10.1038/bjc.2012.519. Epub 2012 Nov 20. Br J Cancer. 2012. PMID: 23169291 Free PMC article.
Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma.
Ghanim B, Hoda MA, Klikovits T, Winter MP, Alimohammadi A, Grusch M, Dome B, Arns M, Schenk P, Jakopovic M, Samarzija M, Brcic L, Filipits M, Laszlo V, Klepetko W, Berger W, Hegedus B. Ghanim B, et al. Among authors: hegedus b. Br J Cancer. 2014 Feb 18;110(4):984-90. doi: 10.1038/bjc.2013.815. Epub 2014 Jan 16. Br J Cancer. 2014. PMID: 24434429 Free PMC article.
Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.
Schelch K, Hoda MA, Klikovits T, Münzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, Filipits M, Pirker C, Heffeter P, Selzer E, Tovari J, Torok S, Kenessey I, Holzmann K, Grasl-Kraupp B, Marian B, Klepetko W, Berger W, Hegedus B, Grusch M. Schelch K, et al. Among authors: hegedus b. Am J Respir Crit Care Med. 2014 Oct 1;190(7):763-72. doi: 10.1164/rccm.201404-0658OC. Am J Respir Crit Care Med. 2014. PMID: 25188816
Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
Ghanim B, Klikovits T, Hoda MA, Lang G, Szirtes I, Setinek U, Rozsas A, Renyi-Vamos F, Laszlo V, Grusch M, Filipits M, Scheed A, Jakopovic M, Samarzija M, Brcic L, Stancic-Rokotov D, Kern I, Rozman A, Dekan G, Klepetko W, Berger W, Glasz T, Dome B, Hegedus B. Ghanim B, et al. Among authors: hegedus b. Br J Cancer. 2015 Mar 3;112(5):783-92. doi: 10.1038/bjc.2015.9. Epub 2015 Jan 29. Br J Cancer. 2015. PMID: 25633038 Free PMC article.
Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.
Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, Stockhammer P, Ozsvar J, Jakopovic M, Samarzija M, Brcic L, Bendek M, Szirtes I, Reid G, Kirschner MB, Kao SC, Opitz I, Weder W, Frauenfelder T, Nguyen-Kim TD, Aigner C, Klepetko W, van Zandwijk N, Berger W, Dome B, Grusch M, Hegedus B. Hoda MA, et al. Among authors: hegedus b. Eur J Cancer. 2016 Aug;63:64-73. doi: 10.1016/j.ejca.2016.04.018. Epub 2016 Jun 8. Eur J Cancer. 2016. PMID: 27288871
Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA, Pirker C, Dong Y, Schelch K, Heffeter P, Kryeziu K, van Schoonhoven S, Klikovits T, Laszlo V, Rozsas A, Ozsvar J, Klepetko W, Döme B, Grusch M, Hegedüs B, Berger W. Hoda MA, et al. Among authors: hegedus b. Mol Cancer Ther. 2016 Oct;15(10):2357-2369. doi: 10.1158/1535-7163.MCT-15-0846. Epub 2016 Aug 10. Mol Cancer Ther. 2016. PMID: 27512118
KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis.
Lohinai Z, Klikovits T, Moldvay J, Ostoros G, Raso E, Timar J, Fabian K, Kovalszky I, Kenessey I, Aigner C, Renyi-Vamos F, Klepetko W, Dome B, Hegedus B. Lohinai Z, et al. Among authors: hegedus b. Sci Rep. 2017 Jan 4;7:39721. doi: 10.1038/srep39721. Sci Rep. 2017. PMID: 28051122 Free PMC article.
188 results